Mortality rates in type 2 diabetes to be discussed at future meeting

By Editor
30th January 2020
Cardiovascular disease, Kidney Type 2 diabetes

A team of multidisciplinary experts have announced details about a meeting which will look at how to lower mortality rates among those with type 2 diabetes using novel anti-diabetes agents.

Organised by the Royal Society of Medicine, ‘Kidneys, heart and diabetes: Science and practice‘, will also look at to new strategies to lower cardiovascular disease (CVD) risk and heart failure hospitalisation.

Attendees will also receive an update on recent clinical trials results, focusing on SGLT2 inhibitors and GLP-1 receptor agonists, highlighting their benefits beyond glycaemic control.

This cross-speciality event will promote collaboration and understanding between general practitioners, cardiologists, nephrologists and endocrinologists working together.

Professor Neil Poulter, Professor of Preventive Cardiovascular Medicine at Imperial College London (UCL), Professor Gerry McKay, Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary, and Professor David Wheeler,
Professor of Kidney Medicine, UCL, Honorary Consultant Nephrologist at the Royal Free Hospital have been confirmed as speakers.

Topics will include

  • Update on reducing thrombosis risk in diabetes – participants will learn to rationally use novel anti-thrombosis agents in high risk patients.
  • Discussing the recent clinical trials results on GLP-1 RAs and SGLT2 inhibitors in type 2 diabetes highlighting these agents benefits in reducing CVD risk, heart failure and kidney disease. Participants will learn how to use these agents rationally and safely promoting collaboration between endocrinologists, primary care, cardiologists and nephrologists.

The event will take place on Tuesday, April 28, from 8:45am to 5:00pm at the Royal Society of Medicine in London.

To book tickets, click here.

Picture credit: National Cancer Institute

Comments (0)

Register an account or login to comment